Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 26, Issue -, Pages 68-70Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2018.09.009
Keywords
Multiple sclerosis; Dimethyl fumarate; Herpes simplex type-1 encephalitis
Categories
Ask authors/readers for more resources
Background: Dimethyl fumarate (DMF) is approved as first line therapy for relapsing-remitting multiple sclerosis (RAMS). In some (3%) patients, DMF induces a marked lymphopenia. Herpes simplex encephalitis (HSE) may occur in lymphopenic subjects under treatment with immune-suppressive drugs. Case presentation: We report a case of a 39-year-old female patient with RAMS that developed HSE temporally associated with a marked and sudden drop in lymphocyte count, from 1200/mu l to 600/mu l, in the peripheral blood. HSE DNA was demonstrated in the cerebrospinal fluid. HSE had the features that characterize HSE occurring in immunosuppressed subjects, i.e. less prominent CSF pleocytosis, bilateral and mainly cortical involvement and less extensive tissue necrosis. Antiviral therapy determined a progressive, although incomplete, improvement. Three months later the patient presented only a mild short-term memory deficit and sporadic episodes of inappropriate emotionality. Lymphocyte count returned to normal values (1120/mu l) after DMF discontinuation. Conclusion: Our case of HSE in a lymphopenic DMF-treated RAMS patient, points out the necessity of further studies on DMF-related lymphopenia, especially whether it implies an impaired immunity against viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available